#032: May 18th, 2021 - Longevity Marketcap Telemetry

1. Announcements

2. Last Week in Longevity

3. Longevity Futures

4. Capital Raise Radar

5. Longevity Jobs

6. New Companies on Longevity List 

7. Humans for Longevity

8. My Links

*Disclaimer: None of this should be taken as financial advice. It is for educational purposes only.

Mission: To grow a wave of passionate people building, funding, and championing technologies that extend healthy human lifespan. 

If you want to be part of this mission alongside me, please consider supporting through Patreon or Longevity List Merch.

📢 Announcements 

• forum.longevitybase.org - I’ve made some improvements to the UI to make it feel more like a “StackExchange / Quora” for aging biology / longevity biotech. Feel free to sign up and try it out. Email me if you would like to become a moderator or if you have some suggestions.

  • For academics, independent researchers, biotech founders, and scientific-minded enthusiasts, etc.

  • Ask questions, get answers → builds a searchable longevity research knowledge base. 

• The Longevity Biotech Show is officially a podcast! Check us out on Spotify and also Apple Podcasts.

• Every Friday @ 12PM - 5PM EDT. Longevity Virtual Coworking. If you are working on longevity or thinking about getting into the longevity industry, please join me for an experimental virtual longevity coworking space using the Pluto.Video web app. (No sign-up required.) 

  • Bring something to work on.

  • Feel free to ask questions. 

  • Help out. Connect.

  • I plan on holding this weekly. It’s free. (Room Link)  

• The 1% Bet for Longevity-- a website initiative. 37 people have now signed up for the 1% Bet for Longevity Pledge. My goal is to get to 50,000 people and at least 100 companies to pledge 1% of their resources towards funding longevity companies and research by the end of the year. 

📝 Last Week in Longevity

• Unity Biotechnology’s UBX1325 passes Phase 1 for diabetic macular edema. Phase 2a trial initiated. Unity Biotechnology is the earliest senolytics company -- founded in 2009 by Ned David, Judith Campisi, Jan van Deursen, and Daohong Zhou. Last week, the company announced that their lead program drug, UBX1325 to treat diabetic macular edema, had passed its Phase 1 safety trial. There were no serious adverse effects and initial data on efficacy will be released later this year. A Phase 2a efficacy trial (that may also enlist wet AMD patients for a parallel trial) is already underway with data expected in 2H